EU HTA Regulation (HTAR)
Regulation (EU) 2021/2282 (the Health Technology Assessment Regulation, HTAR) introduces a centralised Joint Clinical Assessment (JCA) and Joint Scientific Consultation (JSC) at EU level. The first wave — oncology medicines and ATMPs — became subject to JCA from 12 January 2025, with orphan medicines following in January 2028 and all centrally authorised medicines from January 2030.
Read the full summary
High-risk medical devices and IVDs are in scope on a selective basis.
On this page · 9 sections
How does EU HTA Regulation (HTAR) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What HTAR is
HTAR creates an EU-level framework for assessing the relative clinical effectiveness and safety of new health technologies. It does not replace national HTA bodies and does not address pricing or reimbursement — those remain national competences. Instead, JCAs produce a single shared clinical-evidence assessment used as input to national HTA processes, reducing duplication for manufacturers and accelerating access.
02The two core instruments
Joint Clinical Assessment (JCA)
A comparative clinical assessment carried out by Member State assessors under a Coordination Group, producing a JCA report that national HTA bodies must 'duly consider'. Scope is defined by a PICO (Population, Intervention, Comparators, Outcomes) framework consolidated from all participating Member States.
Joint Scientific Consultation (JSC)
Pre-submission scientific advice on the evidence the developer plans to generate. Optional but strongly encouraged. JSC is non-binding and confidential, and runs in parallel with EMA scientific advice where appropriate.
03Scope and phasing
| From | Scope |
|---|---|
| 12 Jan 2025 | New oncology medicinal products and ATMPs with EMA centralised authorisation |
| 12 Jan 2028 | Orphan medicinal products with EMA centralised authorisation |
| 12 Jan 2030 | All medicinal products with EMA centralised authorisation |
| Phased | Selected Class IIb implantables, Class III devices and Class D IVDs — based on annual scoping by the Coordination Group |
04The PICO problem
JCA consolidates PICO questions across all interested Member States into a single assessment. In practice, early JCAs have produced wide PICO matrices with multiple comparators not all studied in the pivotal trial. Manufacturers must plan evidence-generation strategies early — typically starting in Phase II — to cover the likely PICO. JSC is the principal mechanism for getting visibility on the eventual PICO matrix.
05Timing relative to EMA
- JCA is launched alongside the EMA marketing-authorisation procedure.
- The JCA report is finalised within 30 days of EMA CHMP opinion.
- National HTA bodies use the JCA as input; national pricing and reimbursement timelines run as before.
- Late JCA dossier submission delays the entire access pathway — sponsors who under-resource HTAR pay the price downstream.
06Developer obligations
- Notify the Coordination Group of intent to submit an EMA application 9 months before submission.
- Engage JSC for high-uncertainty technologies — early evidence-design alignment is the single biggest determinant of JCA outcome.
- Prepare the JCA dossier in parallel with the EMA dossier; the JCA dossier reuses MAA data but is structured to the PICO matrix.
- Respond to the Assessment Team's questions within tight statutory deadlines.
- Plan post-launch evidence (RWE, registries) to address residual uncertainty flagged in the JCA report.
07Devices in HTAR
JCA for medical devices is selective: the Coordination Group identifies a small number of Class IIb implantables, Class III devices and Class D IVDs each year based on clinical impact, unmet need and EU-level added value. Selection is published in annual work programmes. For devices not selected, national HTA continues unchanged.
08Implications for R&D and clinical strategy
- Pivotal-trial comparator choice must anticipate the EU PICO matrix, not just the EMA primary endpoint requirements.
- Patient-relevant outcomes (HRQoL, functional status) carry more weight in JCA than in many national HTAs historically.
- Subgroup data and indirect treatment comparisons should be planned, not added late.
- RWE plans should be presented as part of the JSC, including registry strategy and post-launch data commitments.
- Health-economic modelling remains national, but the clinical inputs are now harmonised at EU level.
09How V5 handles this
Frequently asked questions
Q.Is the JCA conclusion binding on national HTA bodies?+
No. National HTA bodies must 'duly consider' the JCA but retain full competence on pricing and reimbursement decisions. The JCA harmonises the clinical-evidence input, not the national appraisal.
Q.Does HTAR apply to combination products?+
Yes, where the medicinal-product part is in scope (oncology, ATMP from 2025; orphan from 2028; all centrally authorised from 2030). The device-constituent part follows MDR; HTAR scoping is driven by the medicinal product.
Q.Can JSC be confidential?+
Yes. JSC is confidential and non-binding. The output is a written record of the consultation, available only to the developer and the Assessment Team.
Q.What if Member States want different comparators?+
The Coordination Group consolidates PICO questions into a single matrix. The Assessment Team addresses all consolidated questions in one JCA report. This is the single biggest evidence-generation challenge for sponsors.
Primary sources
Further reading
Want to see how EU HTA Regulation (HTAR) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.